Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.34 |
| ▸ | GPR39 | O43194 | 1/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 6/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | CDC7 | O00311 | 1/20 | 0.33 |
| ▸ | FBP1 | P09467 | 1/20 | 0.33 |
| ▸ | ASPH | Q12797 | 1/20 | 0.33 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | CD38 | P28907 | 1/20 | 0.32 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4423488 | 0.76 | GRM5 (0.41) | KDM4ETSHRHSD17B10MEN1KMT2A | |
| SCHEMBL4424046 | 0.76 | MAPT (0.38) | KDM4ETSHRMEN1KMT2AKDM4C | |
| SCHEMBL8283729 | 0.73 | CHRNB2 (0.33) | TSHR | |
| SCHEMBL4419471 | 0.73 | LMNA (0.33) | TSHR | |
| SCHEMBL4432553 | 0.72 | CYP2C19 (0.50) | MEN1KMT2A | |
| SCHEMBL4433329 | 0.71 | PLK1 (0.39) | CCNT1 | |
| SCHEMBL4421765 | 0.71 | HSD11B1 (0.38) | HSD11B1 | |
| SCHEMBL8284576 | 0.69 | LMNA (0.36) | TSHRMEN1KMT2AS1PR1CDC7 | |
| SCHEMBL4419935 | 0.68 | SMN1; SMN2 (0.42) | HSD17B10MEN1KMT2ACDC7 | |
| SCHEMBL4420035 | 0.66 | KDM4E (0.34) | KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598384-B2 | Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-10-06 | — | — | US | claimed |
| EP-1723116-B1 | TETRAHYDROQUINOLINONES AND THEIR USE AS ANTAGONISTS OF METABOTROPIC GLUTAMATE RECEPTORS | MERZ PHARMA GMBH & CO KGAA (DE) | 2008-09-24 | — | — | EP | claimed |
| EP-1723116-A2 | TETRAHYDROQUINOLINONES AND THEIR USE AS ANTAGONISTS OF METABOTROPIC GLUTAMATE RECEPTORS | Merz Pharma GmbH & Co. KGaA (DE) | 2006-11-22 | — | — | EP | claimed |
| WO-2005082856-A2 | TETRAHYDROQUINOLINONES AND THEIR USE AS ANTAGONISTS OF METABOTROPIC GLUTAMATE RECEPTORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2005-09-09 | — | — | WO | claimed |
| US-20050197361-A1 | Specific binding is extremely high; low toxicity; high degree of activity; 2-(5-m-Tolyl-thiazol-2-yl )-7,8-dihydro-6H-quinolin-5-one, acute and/or chronic neurological disorders | MERZ PHARMA GMBH & CO. KGAA (DE) | 2005-09-08 | — | — | US | claimed |
| US-7598384-B2 | Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-10-06 | — | — | US | disclosed |
| EP-1723116-B1 | TETRAHYDROQUINOLINONES AND THEIR USE AS ANTAGONISTS OF METABOTROPIC GLUTAMATE RECEPTORS | MERZ PHARMA GMBH & CO KGAA (DE) | 2008-09-24 | — | — | EP | disclosed |
| EP-1723116-A2 | TETRAHYDROQUINOLINONES AND THEIR USE AS ANTAGONISTS OF METABOTROPIC GLUTAMATE RECEPTORS | Merz Pharma GmbH & Co. KGaA (DE) | 2006-11-22 | — | — | EP | disclosed |
| WO-2005082856-A2 | TETRAHYDROQUINOLINONES AND THEIR USE AS ANTAGONISTS OF METABOTROPIC GLUTAMATE RECEPTORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2005-09-09 | — | — | WO | disclosed |
| US-20050197361-A1 | Specific binding is extremely high; low toxicity; high degree of activity; 2-(5-m-Tolyl-thiazol-2-yl )-7,8-dihydro-6H-quinolin-5-one, acute and/or chronic neurological disorders | MERZ PHARMA GMBH & CO. KGAA (DE) | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197361-A1 | Specific binding is extremely high; low toxicity; high degree of activity; 2-(5-m-Tolyl-thiazol-2-yl )-7,8-dihydro-6H-quinolin-5-one, acute and/or chronic neurological disorders | GRM5, GRIK5, GRIN2C | KDM4E 2508/4885TSHR 1005/4885HSD17B10 2999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.